
CLAIMS

1. A compound of Formula (IA):



(IA)

or a pharmaceutically acceptable salt thereof, wherein:

X^1 and X^2 are each independently N or CH, provided that at least one of X^1 and X^2 is N;

R^{1a} and R^{1b} are each independently H, halo, or C_1-C_6 alkyl;

R^{2a} and R^{2b} are each independently H, C_1-C_6 alkyl, -O(C_1-C_6 alkyl), -OH, halo, C_1-C_6 haloalkyl, or C_1-C_6 alkyl-OH,

or R^{2a} and R^{2b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_5 cycloalkyl,

or R^{2a} and R^{2b} are taken together to form oxo;

or R^{1a} and R^{2a} are taken together to form a bridging C_2-C_3 alkylene;

R^{3a} and R^{3b} are each independently H, halo, or C_1-C_6 alkyl;

R^{4a} and R^{4b} are each independently H, halo, or C_1-C_6 alkyl,

or R^{4a} and R^{4b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_5 cycloalkyl;

R^{5a} and R^{5b} are each independently H, halo, or C_1-C_6 alkyl;

w is 0 or 1;

R^6 is H or C_1-C_6 alkyl;

R^7 is H or C_1-C_6 alkyl;

x and y are each independently 0 or 1, provided that x and y are not both 1;

R^8 is Cl or -CN;

R^9 is F;

X^3 is N or CH;

z is 0 or 1;

R^{10a} and R^{10b} are each independently H or halo;

R^{11} is H, C_1-C_6 alkyl, -(C_1-C_6 alkylene)-(5- to 6-membered heterocyclyl), -(C_1-C_6 alkylene)-O(C_1-C_6 alkyl), C_1-C_6 haloalkyl, C_1-C_6 alkyl-OH, or -(C_1-C_6 alkylene)-NH(C_1-C_6 alkyl), wherein the heterocyclyl contains 1-3 heteroatoms selected from N, O, and S;

R^{12} is H, halo, or C_1-C_6 alkyl;

R^{13} is H or halo;

R^{14} is H or C_1-C_6 alkyl;

X^4 is N or CR^{15};


R^{15} is H or C_1-C_6 alkyl;

X^5 and X^6 are each independently N or CH; and

═══ is a single or double bond;

wherein one or more hydrogen atoms in the compound are optionally replaced by deuterium.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (I):



(I)

wherein:

X^1 and X^2 are each independently N or CH, provided that at least one of X^1 and X^2 is N;

R^{1a} and R^{1b} are each independently H, halo, or C_1-C_6 alkyl;

R^{2a} and R^{2b} are each independently H, C_1-C_6 alkyl, -OH, halo, or C_1-C_6 alkyl-OH,

or R^{2a} and R^{2b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_5 cycloalkyl,

or R^{2a} and R^{2b} are taken together to form oxo;

or R^{1a} and R^{2a} are taken together to form a bridging C_2-C_3 alkylene;

R^{3a} and R^{3b} are each independently H, halo, or C_1-C_6 alkyl;

R^{4a} and R^{4b} are each independently H, halo, or C_1-C_6 alkyl,

or R^{4a} and R^{4b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_5 cycloalkyl;

R^{5a} and R^{5b} are each independently H, halo, or C_1-C_6 alkyl;

w is 0 or 1;

R^6 is H or C_1-C_6 alkyl;

R^7 is H or C_1-C_6 alkyl;

x and y are each independently 0 or 1, provided that x and y are not both 1;

R^8 is Cl or -CN;

R^9 is F;

X^3 is N or CH;

z is 0 or 1;

R^{10a} and R^{10b} are each independently H or halo;

R^{11} is H, C_1-C_6 alkyl, -(C_1-C_6 alkylene)-(5- to 6-membered heterocyclyl), -(C_1-C_6 alkylene)-O(C_1-C_6 alkyl), C_1-C_6 haloalkyl, C_1-C_6 alkyl-OH, or -(C_1-C_6 alkylene)-NH(C_1-C_6 alkyl), wherein the heterocyclyl contains 1-3 heteroatoms selected from N, O, and S;

R^{12} is H, halo, or C_1-C_6 alkyl;

R^{13} is H or halo;

R^{14} is H or C_1-C_6 alkyl;

X^4 is N or CR^{15};

R^{15} is H or C_1-C_6 alkyl;

X^5 and X^6 are each independently N or CH; and

$\equiv$ is a single or double bond;

wherein one or more hydrogen atoms in the compound are optionally replaced by deuterium.

3. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: X^1 is CH and X^2 is N; or X^1 is N and X^2 is CH .

4. The compound of claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein: X^1 and X^2 are each N.

5. The compound of any one of claims 1-4, or a pharmaceutically acceptable salt thereof, wherein:

R^{1a} and R^{1b} are each independently H, halo, or C_1-C_3 alkyl.

6. The compound of any one of claims 1-5, or a pharmaceutically acceptable salt thereof, wherein:

R^{2a} and R^{2b} are each independently H, C_1-C_3 alkyl, -OH, halo, or C_1-C_3 alkyl-OH,

or R^{2a} and R^{2b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_4 cycloalkyl,

or R^{2a} and R^{2b} are taken together to form oxo.

7. The compound of any one of claims 1-6, or a pharmaceutically acceptable salt thereof, wherein:

R^{3a} and R^{3b} are each independently H, halo, or C_1-C_3 alkyl.


8. The compound of any one of claims 1-7, or a pharmaceutically acceptable salt thereof, wherein:


R^{4a} and R^{4b} are each independently H, halo, or C_1-C_3 alkyl,

or R^{4a} and R^{4b} are taken together with the carbon atom to which they are attached to form a spiro C_3-C_4 cycloalkyl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein:

R^{5a} and R^{5b} are each independently H, halo, or C_1-C_3 alkyl.


10. The compound of any one of claims 1-9, or a pharmaceutically acceptable salt thereof, wherein  is:




11. The compound of any one of claims 1-10, or a pharmaceutically acceptable salt thereof, wherein:

R^{11} is H, C_1-C_3 alkyl, -(C_1-C_3 alkylene)-(6-membered heterocyclyl), -(C_1-C_3 alkylene)-O(C_1-C_3 alkyl), C_1-C_5 haloalkyl, C_1-C_5 alkyl-OH, or -(C_1-C_3 alkylene)-NH(C_1-C_3 alkyl), wherein the heterocyclyl contains 1-2 heteroatoms selected from N and O.


12. The compound of any one of claims 1-11, or a pharmaceutically acceptable salt thereof,




wherein is:





13. The compound of any one of claims 1-12, or a pharmaceutically acceptable salt thereof,

wherein  is:




14. The compound of any one of claims 1-13, or a pharmaceutically acceptable salt thereof,


wherein  is:




15. The compound of any one of claims 1-14, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (II), (III), or (IV):



(II)




(III)



(IV)

16. The compound of claim 15, or a pharmaceutically acceptable salt thereof, wherein the compound is of Formula (IIIb):



(IIIb) .


17. A compound selected from the compounds of Table 1 and pharmaceutically acceptable salts thereof.

18. A pharmaceutical composition comprising the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

19. A method of degrading B-cell lymphoma 6 protein (BCL6) comprising contacting BCL6 with an effective amount of the compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 18.

20. The compound of any one of claims 1-17, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 18, for use in a method of treating a cancer or an autoimmune disease in a subject in need thereof.

21. A compound of the following formula:



,

or a pharmaceutically acceptable salt thereof.


22. A pharmaceutical composition comprising the compound of claim 21, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

23. The compound of claim 21, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 22, for use in a method of treating Non-Hodgkin's lymphoma in a subject in need thereof.

24. The compound of claim 21, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 22, for use in a method of treating Diffuse Large B-cell Lymphoma in a subject in need thereof.

25. The compound of claim 21, or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 22, for use in a method of treating follicular lymphoma in a subject in need thereof.

26. The compound of claim 21, having the following formula:



.

27. A pharmaceutical composition comprising the compound of claim 26 and a pharmaceutically acceptable excipient.

28. The compound of claim 26, or the pharmaceutical composition of claim 27, for use in a method of treating Non-Hodgkin's lymphoma in a subject in need thereof.

29. The compound of claim 26, or the pharmaceutical composition of claim 27, for use in a method of treating Diffuse Large B-cell Lymphoma in a subject in need thereof.

30. The compound of claim 26, or the pharmaceutical composition of claim 27, for use in a method of treating follicular lymphoma in a subject in need thereof.